Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Relapsing-remitting multiple sclerosis (RRMS) is a chronic autoimmune disease affecting the central nervous system.
• Current treatments aim to reduce disease activity and disability progression.
• Interferon beta-1a (IFNβ-1a) is a standard therapy, but patient responses can vary.

Purpose of the Study:

• To compare the efficacy of fingolimod versus intramuscular interferon beta (IFNβ)-1a in patients with RRMS.
• To analyze treatment effects in various patient subgroups based on demographics and disease characteristics.
• To evaluate outcomes including relapse rates and magnetic resonance imaging (MRI) measures.

Main Methods:

• Phase 3, 12-month TRANSFORMS study.
• Randomized patients to fingolimod or weekly IM IFNβ-1a.
• Efficacy assessed by annualized relapse rate (ARR) and MRI measures (Gd-enhancing T1 lesions, active T2 lesions, brain volume change).
• Subgroup analyses based on demographics, baseline disease characteristics, and prior treatment response.

Main Results:

• Fingolimod 0.5 mg significantly reduced ARR by 32-59% compared to IFNβ-1a across all demographic and baseline disease characteristic subgroups.
• Fingolimod demonstrated greater reductions in new Gd-enhancing lesions, active T2 lesions, and brain volume loss versus IFNβ-1a in 95% of subgroups.
• In patients with high disease activity despite prior IFNβ treatment, fingolimod reduced ARR by 61% and improved MRI outcomes compared to IFNβ-1a.

Conclusions:

• Fingolimod consistently showed greater efficacy than IFNβ-1a in patients with RRMS.
• Treatment benefits with fingolimod were observed across diverse patient subgroups.
• Fingolimod represents a more effective therapeutic option for RRMS patients, including those with high disease activity.